# Ken Sato

## List of Publications by Year in descending order



| | | | |
|---|---|---|---|
| 32 papers | 777 citations | 687363 13 h-index | 501196 28 g-index |
| 33 all docs | 33 docs citations | 33 times ranked | 941 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1bâ€“infected Japanese patients with or without cirrhosis. Hepatology, 2015, 62, 1037-1046. | 7.3 | 146 |
| 2 | Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. Journal of Gastroenterology, 2018, 53, 566-575. | 5.1 | 107 |
| 3 | Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. Journal of Gastroenterology, 2018, 53, 557-565. | 5.1 | 103 |
| 4 | Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology, 2018, 67, 505-513. | 7.3 | 94 |
| 5 | Randomized trial of interferonâ€•and ribavirinâ€free ombitasvir/paritaprevir/ritonavir in treatmentâ€experienced hepatitis C virusâ€“infected patients. Hepatology, 2015, 61, 1523-1532. | 7.3 | 78 |
| 6 | Expression of amino acid transporters (<scp>LAT1</scp>, <scp>ASCT2</scp> and <scp>xCT</scp>) as clinical significance in hepatocellular carcinoma. Hepatology Research, 2015, 45, 1014-1022. | 3.4 | 51 |
| 7 | Analyses of objective response rate, progressionâ€free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study. Hepatology Research, 2020, 50, 382-395. | 3.4 | 28 |
| 8 | Realâ€world efficacy and safety of 12â€week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Hepatology Research, 2021, 51, 51-61. | 3.4 | 20 |
| 9 | Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment. Cancers, 2020, 12, 2906. | 3.7 | 17 |
| 10 | Spleen Stiffness Correlates with the Presence of Ascites but Not Esophageal Varices in Chronic Hepatitis C Patients. BioMed Research International, 2013, 2013, 1-7. | 1.9 | 16 |
| 11 | Clinical and virological features of acute hepatitis E in Gunma prefecture, Japan between 2004 and 2015. Hepatology Research, 2017, 47, 435-445. | 3.4 | 16 |
| 12 | Spontaneous remission of hepatitis B virus reactivation during directâ€acting antiviral agentâ€based therapy for chronic hepatitis C. Hepatology Research, 2017, 47, 1346-1353. | 3.4 | 14 |
| 13 | Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients. Advances in Therapy, 2017, 34, 1449-1465. | 2.9 | 14 |
| 14 | Full genome analysis of a European-type genotype 3 hepatitis E virus variant obtained from a Japanese patient with autochthonous acute hepatitis E. Journal of Medical Virology, 2015, 87, 1067-1071. | 5.0 | 10 |
| 15 | Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin. Hepatology Research, 2018, 48, E347-E353. | 3.4 | 10 |
| 16 | Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling. World Journal of Hepatology, 2020, 12, 350-362. | 2.0 | 8 |
| 17 | A Prospective Randomized Controlled Trial of AJG522 versus Standard PEG + E as Bowel Preparation for Colonoscopy. BioMed Research International, 2015, 2015, 1-8. | 1.9 | 7 |
| 18 | New endoscopic classification of cascade stomach, a risk factor for reflux esophagitis. Journal of Gastroenterology, 2017, 52, 211-217. | 5.1 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Favorable outcome of retreatment by directâ€acting antivirals for hepatitisÂC patients with daclatasvir plus asunaprevir combination therapy failure. Hepatology Research, 2020, 50, 303-312. | 3.4 | 5 |
| 20 | Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus. World Journal of Gastroenterology, 2018, 24, 4304-4310. | 3.3 | 5 |
| 21 | Successful prolonged treatment of glecaprevir/pibrentasvir for chronic hepatitis C patient with treatment failure after 8-week therapy: a case report. Clinical Journal of Gastroenterology, 2019, 12, 592-597. | 0.8 | 3 |
| 22 | A case of chronic hepatitis C accompanied by marked thrombocytopenia during combination therapy with daclatasvir and asunaprevir. Acta Hepatologica Japonica, 2015, 56, 603-609. | 0.1 | 2 |
| 23 | Minimizing the effect of warfarin potassium during daclatasvir/asunaprevir combination therapy in a case of chronic hepatitis C after aortic dissection. Acta Hepatologica Japonica, 2017, 58, 22-27. | 0.1 | 2 |
| 24 | Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C. Biomedicines, 2021, 9, 660. | 3.2 | 2 |
| 25 | Successful treatment of Japanese hemophilia patient co-infected with HIV and HCV genotype 4a by glecaprevir/pibrentasvir therapy. Clinical Journal of Gastroenterology, 2021, 14, 1725-1732. | 0.8 | 2 |
| 26 | Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19. World Journal of Gastroenterology, 2021, 27, 8370-8373. | 3.3 | 2 |
| 27 | Sofosbuvir/Ribavirin therapy for patients experiencing failure of ombitasvir/paritaprevir/ritonavir + ribavirin therapy: Two cases report and review of literature. World Journal of Clinical Cases, 2019, 7, 1043-1052. | 0.8 | 1 |
| 28 | Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately. Internal Medicine, 2021, 60, 3061-3070. | 0.7 | 1 |
| 29 | Characteristics of cases of hepatitis E in 2019 in Gunma prefecture: a small epidemic caused by the same subgenotype 3a strain. Acta Hepatologica Japonica, 2020, 61, 478-481. | 0.1 | 1 |
| 30 | Adolescents with chronic hepatitis C might be good candidates for directâ€acting antiviral therapy. Clinical Case Reports (discontinued), 2022, 10, e05690. | 0.5 | 1 |
| 31 | Frequency of null genotypes of glutathione Sâ€transferase M1 and T1 in Japanese patients with drugâ€induced liver injury. Hepatology Research, 0, , . | 3.4 | 1 |
| 32 | A patient with type I Gaucher disease who switched from enzyme replacement therapy to substrate reduction therapy after having of CYP2D6 polymorphisms checked. Acta Hepatologica Japonica, 2018, 59, 243-251. | 0.1 | 0 |